Cellectis announced the resignation of Mr. Bing Wang from his position of the company with immediate effect, and the concomitant appointment of Mr. Arthur Stril as interim Chief Financial Officer, replacing Mr. Bing Wang. Mr. Stril joined the company in 2018 as Vice President, Corporate Development, and was appointed Chief Business Officer in 2020. He has been managing the company?s business development and portfolio management teams and most recently led the execution of the company?s strategic collaboration and investment agreements with AstraZeneca.

As interim Chief Financial Officer, Mr. Stril will oversee the finance and investor relations functions, and continue to oversee the business development functions. He will remain based in the company?s New York office. Mr. Stril, age 35 began his career at the European Commission?s Directorate-General for Competition, controlling global pharmaceutical mergers.

He later became head of the Hospital Financing Unit at the French Ministry of Health. Since 2023, Mr. Stril serves on the board of directors of Primera Therapeutics as a director designated by the company. Mr. Stril graduated with a Master of Mathematics from Cambridge University and a Master of Physics from the École Normale Supérieure and holds immunotherapy and immuno-oncology diplomas from the University of Paris.

Mr. Stril is also a member of the French Corps des Mines and is on the Board of Advisors of non-profit Life Science Cares.